Nicholas Plummer - 01 Aug 2025 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Reporting relationship: GC - Volition Diagnostics
Issuer ticker: VNRX
Reported as of: 01 Aug 2025
Net transaction value: -$2,849
SEC form: 4
Accepted by SEC: 05 Aug 2025, 16:01:25 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Nicholas Plummer

Key filing fact

Nicholas Plummer filed Form 4 for VOLITIONRX LTD (VNRX) on 05 Aug 2025.

Key facts

This page summarizes Nicholas Plummer's Form 4 filing for VOLITIONRX LTD (VNRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Aug 2025, 16:01.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: -$2,849.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001880653 Primary reporting owner

Plummer Nicholas

Relationship: GC - Volition Diagnostics
Address: 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON
Signature: /s/ Nicholas Plummer
Signature date: 05 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNRX transaction

Common Stock

Tax liability

Transaction value: $2,849
Shares: -4,451
Change %: -2.4%
Price: $0.6400
Shares after: 183,846
Date: 01 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,086 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.